74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Royalty Pharma PLC (Class A)
Closed
SectorHealthcare
32.04 1.17
Overview
Share price change
24h
Min
31.45
Max
32.12
Income | 441M 334M |
|---|---|
Sales | 29M 594M |
P/E Sector Avg | 16.853 57.333 |
EPS | 1.151 |
Dividend yield | 2.7 |
Profit margin | 56.288 |
EBITDA | -511M 362M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +23.86% upside |
Dividend yield Sector Avg | 2.70% 2.63% |
|---|---|
Next Earnings | 8 May 2025 |
Next Dividend date | 10 Jun 2025 |
Next Ex Dividend date | 16 May 2025 |
Market Cap | 18B |
|---|---|
Previous open | 30.87 |
Previous close | 32.04 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Royalty Pharma PLC (Class A) Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Royalty Pharma PLC (Class A) Forecast
Price Target
By TipRanks
23.86% upside
12 Months Forecast
Average 39.25 USD 23.86%
High 42 USD
Low 33 USD
Based on 4 Wall Street analysts offering 12 month price targets forRoyalty Pharma PLC (Class A) - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Royalty Pharma PLC (Class A)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
